Presentation

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

European Congress of Endocrinology

2024

Presentation

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

Heart in Diabetes

2024

Poster

Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond

Heart in Diabetes

2024

Poster

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: results from CATALYST

World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

2024

Poster

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST

World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

2024

Presentation

Relacorilant improved blood pressure and maintained other cardiometabolic improvements in long-term study in patients with endogenous hypercortisolism (Cushing syndrome).

World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

2024

Poster

Open-label extension study evaluating the safety and efficacy of long-term use of relacorilant in patients with endogenous hypercortisolism (cushing syndrome): interim analysis results

World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

2024

Poster

Medical treatment of hypercortisolism with relacorilant: final results of the phase 3 grace study

World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

2024

Poster

A Phase 1, Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-gp Substrate Dabigatran Etexilate in Healthy Subjects

American Association of Pharmaceutical Scientists

2024

Poster

Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)

American Association of Clinical Endocrinology - Middle East & North Africa

2024

Poster

Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)

Annual Meeting of The Endocrine Society

2024

Poster

Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone

American Association of Clinical Endocrinology

2024